Sermorelin · DOSSIER

Sermorelin

GHRH(1-29)-NH₂ · GRF(1-29) · Peptide · 29 AS
LEGAL DE · NOT APPROVEDEVIDENCE · EARLY CLINICAL STUDIES3 STUDIESWADA · S2
FIG.01 — SIGNAL CHAIN
YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH₂ · ~3357.9 Da
02

Mechanism of action

What Sermorelin does in the body — step by step.

01

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH) — the shortest sequence that still retains full biological activity at the GHRH receptor (GHRHR).

02

By binding to GHRHR in the somatotroph cells of the anterior pituitary, sermorelin stimulates the synthesis and pulsatile release of growth hormone (GH).

03

Compared with CJC-1295, sermorelin has a shorter biological half-life (approx. 10–20 minutes), producing more physiological, short-lived GH pulses than long-acting GHRH analogs.

03

Research status

How far along is the evidence?

PRECLINICALEARLY CLINICAL STUDIESCLINICALLY ESTABLISHED
In the USA, sermorelin was approved as Geref from 1997 to 2002 for the treatment of idiopathic growth hormone deficiency in children (withdrawn from the market for commercial, not safety, reasons).
In the USA, sermorelin was approved as Geref from 1997 to 2002 for the treatment of idiopathic growth hormone deficiency in children (withdrawn from the market for commercial, not safety, reasons).
Clinical studies documented improved body composition, increased bone density and reduced body fat in GH-deficient adults.
In an anti-aging medical context, sermorelin is used off-label in the USA as an alternative to exogenous HGH; controlled studies for this use in healthy adults are largely lacking.
Its effect depends on intact pituitary function — insufficient in cases of severe GH-axis damage.
04

Known risks

Without human data, safety statements are limited. What is known:

01
Flushing and dizziness possible shortly after injection (vasodilatory effect)
02
Headache described at higher doses
03
Pituitary function required — without an intact GH axis, insufficient effect
04
Fluid retention due to GH/IGF-1 increase
05
No data on long-term use in healthy adults
05

Cited studies

Chronological — links lead to the source.

1998
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
PubMed 9554037 →
2006
Effects of sermorelin on body composition in adults with growth hormone deficiency
PubMed 16352686 →
2010
Growth hormone-releasing hormone(1-29) normalizes sleep and the GH/IGF-I axis in patients with depression
PubMed 20566617 →
06

Frequently asked questions

What is Sermorelin?+

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH) — the shortest sequence that still retains full biological activity at the GHRH receptor (GHRHR).

What type of peptide is Sermorelin?+

Sermorelin belongs to the GHRH analog class.

What is Sermorelin used for?+

In research, Sermorelin has primarily been investigated in the context of: Muscle growth, Anti-aging. These are research findings (evidence: early clinical studies), not proven benefits in humans and not a usage recommendation.

Is Sermorelin legal in Germany?+

Sermorelin is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.

Is Sermorelin FDA-approved / legal in the US?+

The FDA status of Sermorelin is not clearly classified.

Is Sermorelin legal in Canada?+

The regulatory status of Sermorelin in Canada is not clearly classified.

Where can I buy Sermorelin?+

Peptica sells nothing and names no sources. Sermorelin is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

What is the dosage of Sermorelin?+

Peptica publishes no dosing. There are no approved dosing guidelines for Sermorelin; figures circulating online stem from animal studies or anecdote, not from validated human protocols. This is not medical advice.

Is Sermorelin banned in sport (WADA)?+

Yes. Sermorelin is on the WADA Prohibited List and is therefore banned in competitive sport.

What are the known risks of Sermorelin?+

Documented risks include: Flushing and dizziness possible shortly after injection (vasodilatory effect); Headache described at higher doses. This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is Sermorelin?+

The evidence is classified as “early clinical studies”. 3 studies are cited on this page.

What is the molecular weight of Sermorelin?+

Sermorelin has a molar mass of about 3357.9 Da, with a plasma half-life of ~10–20 minutes.

Which peptides are related to Sermorelin?+

Closely related entries: CJC-1295, Ipamorelin, Tesamorelin, GHRP-2. A direct side-by-side comparison is available via the compare function.

07

Dossier

Legal · Structure · Sources.

LEGAL STATUS BY REGION
Germanynot approved

Sermorelin is not approved as a medicine in the EU. The US approval was voluntarily withdrawn in 2002 for commercial reasons, not safety reasons. As a GHRH analog, sermorelin is listed on the WADA Prohibited List (S2). Importing it without a medical prescription in Germany is legally problematic (AMG).

Legal status varies by country and can change. This is not legal advice.

STRUCTURE & MOLECULE
H₂NYADAIFTNSYRKVLGQLSARKLLQDIMSR-NHCOOH
29
AMINO ACIDS
~3357.9
MOL. WEIGHT (Da)
~10–20 minutes
HALF-LIFE
SOURCES & EXTERNAL DATABASES

Methodology: Peptica compiles publicly available studies and regulatory information and assigns each statement an evidence level. Not medical advice. No warranty.

RELATED PEPTIDES & FURTHER READING
08

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.
This page is intended solely for factual, scientifically oriented information. No medical advice · no dosage or usage recommendations · no claims of efficacy · no substitute for medical consultation. Peptica sells no substances. Partner links are marked as advertising; Peptica may earn a commission. © 2026 Peptica · Issue 01